Posted by Michael Wonder on 28 Mar 2025
Takeda’s HyQvia receives expanded market authorisation as maintenance therapy for chronic inflammatory demyelinating polyneuropathy
27 March 2025 - HyQvia is the only up to once monthly (every 2, 3 or 4 weeks) immunoglobulin subcutaneous infusion to treat CIDP in Canada
Takeda Canada is pleased to announce that Health Canada has expanded the marketing authorisation for HyQvia (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion) for chronic inflammatory demyelinating polyneuropathy as maintenance therapy after stabilisation with intravenous immunoglobulin to prevent relapse of neuromuscular disability and impairment in adults.
